Omnipod 5 improves diabetes control in clinical trial

ACTON, Mass. - Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology with a market capitalization of $18.66 billion and impressive revenue growth of 22% over the last twelve months, has announced the results of its RADIANT study, demonstrating significant benefits for type 1 diabetes patients transitioning from multiple daily injections (MDI) to its Omnipod 5 Automated Insulin Delivery (AID) System. According to InvestingPro analysis, the company is currently trading near its Fair Value, maintaining a "GREAT" overall financial health score. The study’s findings were presented at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Amsterdam, Netherlands.

The RADIANT trial, involving 188 participants aged 4 to 70 years with type 1 diabetes and HbA1c levels between 7.5% and 11%, is the first to evaluate the direct switch from MDI to an AID system. Over a three-month period, those using the Omnipod 5 system experienced an average HbA1c decrease of 0.8%, with even greater benefits for individuals starting with HbA1c levels above 8.0%. The company’s strong market position is reflected in its robust gross profit margin of 69.79% and healthy current ratio of 3.58, as reported by InvestingPro, which offers comprehensive analysis through its Pro Research Reports covering 1,400+ top stocks.

Additionally, Omnipod 5 users spent 5.4 more hours per day within the target glucose range (70-180mg/dL) without an increase in hypoglycemia. The study reported no severe hypoglycemia or ketoacidosis events in either treatment group.

Dr. Trang Ly, Insulet Senior Vice President and Chief Medical Officer, highlighted the therapeutic benefits of Omnipod 5, which is used by an estimated 365,000 individuals worldwide. Dr. Emma G. Wilmot and Professor Hélène Hanaire, both involved in the study, emphasized the safety and ease of transitioning directly to Omnipod 5 from MDI, suggesting immediate benefits for patients.

Insulet plans to submit the RADIANT study results for publication later this year. The company serves approximately 5.2 million people with type 1 diabetes across 25 countries, including the U.S. and 10 other countries where Omnipod 5 is commercially available.

This article is based on a press release statement from Insulet Corporation. For deeper insights into Insulet’s financial performance and growth prospects, including 12 additional exclusive ProTips and detailed financial metrics, visit InvestingPro.

In other recent news, Insulet Corporation has reported several significant developments. The company announced the pricing of a private placement of $450 million in senior unsecured notes with a 6.50% annual interest rate, maturing in 2033. This move is part of a broader strategy to manage its existing debt, including the repayment of its 0.375% Convertible Senior Notes due in 2026. Moody’s Ratings has upgraded Insulet’s Corporate Family Rating to Ba3, reflecting the company’s healthy earnings growth and strong liquidity position. S&P Global Ratings also upgraded Insulet’s credit rating from ’BB-’ to ’BB’, citing strong operating performance and expected deleveraging. The company has seen a 22% increase in full-year 2024 revenue and a 33% rise in EBITDA, driven by the adoption of its Omnipod 5 Automated Insulin Delivery System. Furthermore, Insulet has extended its agreement with NXP USA, amending terms related to pricing and volume commitments to secure a stable supply chain. These developments indicate Insulet’s focus on maintaining financial stability and operational efficiency.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.